Business / Finance

RSS

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma, today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company's amino acid based products to physicians and pharmacies throughout the Middle East.

17 Apr 2014

Nora Therapeutics closes $18M Series B financing to expand drug development

Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing.

17 Apr 2014

College of American Pathologists and ASC sign MOU to advance delivery of cytopathology services

The College of American Pathologists and the American Society of Cytopathology announced today the signing of a memorandum of understanding (MOU) to collaborate on initiatives to advance the delivery of cytopathology services and improve patient care.

17 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Hooper Holmes enters into Strategic Alliance Agreement with Clinical Reference Laboratory

Hooper Holmes and Clinical Reference Laboratory, Inc. today announced that they have entered into a Strategic Alliance Agreement under which CRL will become Hooper Holmes' exclusive provider of laboratory testing services and Hooper Holmes will become a member of CRL's preferred provider network for wellness programs.

16 Apr 2014

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.

16 Apr 2014

St. Jude Medical's net sales increase 2% in first quarter 2014

St. Jude Medical, Inc. today reported sales and net earnings for the first quarter ended March 29, 2014.

16 Apr 2014

Wilson Therapeutics closes $40 million Series B financing

Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partners LLP. The company's founding investor, HealthCap, also participated in the round.

16 Apr 2014

Bioniche Life Sciences sells Animal Health business to Vétoquinol

Vétoquinol and Bioniche Life Sciences Inc., today jointly announced the closing of the sale of Bioniche's Animal Health business to Vétoquinol.

16 Apr 2014

Eating Recovery Center collaborates with Eating Disorder Center at San Antonio

Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA).

16 Apr 2014

EventusDx completes $2.72M financing to support development, commercialization of Octava breast cancer tests

Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.

15 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Prestige Brands Holdings, Inc. today announced the signing of a purchase agreement for the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. The acquisition is expected to close, subject to customary closing conditions, during the first quarter of fiscal 2015, which began on April 1, 2014.

15 Apr 2014

Kineta, RLB Holdings form joint venture to address unmet medical needs

Kineta, Inc., a biotechnology company focused on the development of immune-modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture, Kineta RLB, LLC, which will commercialize promising, high-value compounds in selective disease areas with unmet medical needs.

15 Apr 2014

Sanofi Korea launches gut health product, Probi Digestis

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.

15 Apr 2014

PENTAX Medical, Hitachi Medical Systems renew partnership in the area of endoscopic ultrasound

PENTAX Europe and Hitachi Medical Systems Europe have been working together for more than twenty years and today announced a renewal of their strategic partnership in UK to the benefit of their customers.

From PENTAX Medical Company 15 Apr 2014

AMETEK, Zygo enter into definitive merger agreement

AMETEK, Inc. and Zygo Corporation announced that they have entered into a definitive merger agreement under which AMETEK will acquire all of the outstanding shares of common stock of Zygo at a purchase price of $19.25 per share in cash, which represents a premium of 31% to Zygo's closing share price on April 10, 2014.

11 Apr 2014

Bio-Rad Laboratories buys GnuBIO

GnuBIO, a privately-held life sciences company that has developed a droplet-based DNA sequencing technology, today announced that it was acquired by Bio-Rad Laboratories, Inc. With this acquisition, Bio-Rad will expand its Digital Biology Center and establish a research and development site in Cambridge, Massachusetts.

11 Apr 2014

Cognizant collaborates with HTH Worldwide to maximize mobile healthcare solutions

Cognizant today announced that it is working with HTH Worldwide, a global technology-based health services and information company, to enable its members to maximize the use of mobile technology for managing healthcare needs more effectively while traveling abroad. As part of the engagement, Cognizant is helping HTH Worldwide transform its mobile footprint through an enterprise mobile platform to support the company's rapidly growing business and further strengthen its leadership position in mobile medical assistance services.

11 Apr 2014

Nexstim joins 2014 Red Herring mark of distinction

Red Herring's Top 100 Europe celebrates the exceptional accomplishments of technology companies and their position to grow at an explosive rate. The awards winners were announced today, and Nexstim has proudly been selected in this prestigious group as a Top 100 Europe.

11 Apr 2014